Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Human Resources | May 03, 2016 | May 06, 2016 |
| MANNKIND CORPMNKD · Entity 4792 | Chief People & Workpl Officer | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date May 03, 2016 · Filed May 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,671 |
Reported balance
After 2016-05-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-05-03 · Grant · Acquired 2,046 · Balance 25,671 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.35 · Expires 2026-05-03 | Direct | 17,422 |
Reported balance
After 2016-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-05-03 · Grant · Acquired 17,422 · Balance 17,422 F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 593.142 |
Reported balance
Holding disclosure · report date 2016-05-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 593.142 F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
F2: These shares include the following RSUs granted under the Company's equity plans: 334 RSUs which vest on 4/26/2017; 2,131 RSUs which vest in one installment of 1,049 on 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,127 RSUs which vest in two installments of 555 and 572 on 1/31/2017 and 1/31/2018, respectively; 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019; and 2,046 RSUs which vest in two equal installments of 675 on 5/3/2018 and 5/3/2019 and one installment of 696 on 5/3/2020. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 225 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4: These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.
F5: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2018, 5/3/2019 and 5/3/2020, respectively.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,123,950 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 93,790 · Balance 1,123,950 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,090,298 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 33,652 · Balance 1,090,298 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,082,045 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 8,253 · Balance 1,082,045 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,070,473 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 11,572 · Balance 1,070,473 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 1,058,142 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 12,331 · Balance 1,058,142 F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-15 · Exercise / conversion · Disposed 93,790 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2: Includes 4,038 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2026.
F3: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F4: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2015 Filed Mar 5, 2015 01:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 4,415 | $157.74 | $696,426.52 |
DisclosureSEC source: 0001127602-15-010218 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,237 F1 · price: The price reported is an average price. The prices ranged from $157.76 to $157.74 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 30, 2015 Filed Feb 4, 2015 00:16 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-15-004148 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,652 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/30/2017, 1/30/2018 and 1/30/2019, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively; and 1,576 RSUs which vest in two equal installments of 520 on 1/30/2017 and 1/30/2018 and one installment of 536 on 1/30/2019. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 179 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 01, 2014 Filed Sep 3, 2014 00:30 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,292 | $139.38 | $1,016,358.96 |
DisclosureSEC source: 0001127602-14-026970 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,022 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 125 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7 | $111.41 | $779.87 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 4 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,204 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 608 RSUs which vest in one installment on 4/25/2015; 885 RSUs which vest in two annual installments of 436 and 449 on 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 610 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 22:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 164 | $111.41 | $18,271.24 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 3 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,211 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 22:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 137 | $111.41 | $15,263.17 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 22:05 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 222 | $113.72 | $25,245.84 |
DisclosureSEC source: 0001127602-14-015515 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,512 Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 20:41 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,647 | $123.96 | $204,162.12 |
DisclosureSEC source: 0001127602-14-012057 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,734 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 626 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 05, 2014 Filed Mar 7, 2014 22:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-010763 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,273 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 518 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 23:10 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-004402 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,892 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017; 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017; and 1,681 RSUs which vest in three installments of 554, 555 and 572 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 518 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| October 25, 2013 Filed Oct 29, 2013 22:12 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 3,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-029947 · form4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,128 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 10/25/2015, 10/25/2016 and 10/26/2017, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 362 RSUs which fully vest on 4/26/2014; 1,197 RSUs which vest in one installment of 589 on 4/25/2014 and one installment of 608 on 4/25/2015; 1,320 RSUs which vest in three installments of 435, 436 and 449 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 13,958 RSUs which fully vest on 9/1/2014; 982 RSUs which vest in two equal installments of 324 each on 4/26/2015 and 4/26/2016 and one installment of 334 on 4/26/2017 and 3,180 RSUs which vest in two equal installments of 1,049 each on 10/25/2015 and 10/25/2016 and one installment of 1,082 on 10/25/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 435 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.